inventiva
participate
several
investor
conferences
october
paris
stock
exchange
iva
daix
france
september
inventiva
euronext
paris
nasdaq
iva
biopharmaceutical
company
focused
development
oral
small
molecule
therapies
treatment
steatohepatitis
nash
mucopolysaccharidoses
mps
diseases
significant
unmet
medical
need
today
announced
management
team
participate
four
investor
conferences
october
event
details
follows
conference
portzamparc
health
biotech
virtual
seminar
date
thursday
october
time
eastern
time
pm
pm
paris
time
format
virtual
event
conference
wainwright
annual
nash
virtual
investor
conference
date
monday
october
format
virtual
event
conference
healthtech
innovation
days
date
october
format
virtual
physical
event
link
event
http
conference
european
midcap
hybrid
event
date
october
format
virtual
physical
event
link
event
http
inventiva
inventiva
biopharmaceutical
company
focused
development
oral
small
molecule
therapies
treatment
nash
mps
diseases
significant
unmet
medical
need
leveraging
expertise
experience
domain
compounds
targeting
nuclear
receptors
transcription
factors
epigenetic
modulation
inventiva
currently
advancing
two
clinical
candidates
well
deep
pipeline
earlier
stage
programs
lanifibranor
lead
product
candidate
developed
treatment
patients
nash
common
progressive
chronic
liver
disease
currently
approved
therapies
inventiva
recently
announced
positive
topline
data
phase
iib
clinical
trial
evaluating
lanifibranor
treatment
patients
nash
inventiva
also
developing
odiparcil
second
clinical
stage
asset
treatment
patients
subtypes
mps
group
rare
genetic
disorders
phase
ii
clinical
trial
children
mps
vi
currently
preparation
following
release
positive
results
phase
iia
clinical
trial
adult
mps
vi
patients
end
parallel
inventiva
process
selecting
oncology
development
candidate
hippo
signalling
pathway
program
furthermore
company
established
strategic
collaboration
abbvie
area
autoimmune
diseases
abbvie
started
clinical
development
drug
candidate
treatment
moderate
severe
psoriasis
resulting
collaboration
inventiva
collaboration
enables
inventiva
receive
milestone
payments
upon
achievement
clinical
regulatory
commercial
milestones
addition
royalties
approved
products
resulting
collaboration
company
scientific
team
approximately
people
deep
expertise
fields
biology
medicinal
computational
chemistry
pharmacokinetics
pharmacology
well
clinical
development
also
owns
extensive
library
approximately
pharmacologically
relevant
molecules
approximately
proprietary
well
research
development
facility
inventiva
public
company
listed
compartment
c
regulated
market
euronext
paris
euronext
iva
isin
nasdaq
global
market
united
states
ticker
iva
contacts
inventiva
frédéric
cren
chairman
ceo
info
brunswick
group
yannick
tetzlaff
tristan
roquet
montegon
aude
lepreux
media
relations
inventiva
westwicke
icr
patricia
bank
investor
relations
attachment
